Strategic collaborations Crescendo Biologics maintains multi-target discovery and development collaborations with Takeda and BioNTech, along with an exclusive global licensing deal with Zai Lab. This indicates a strong partner-driven growth model and potential co-development or licensing discussions for additional Humabody therapies or pipeline extensions.

Clinical-stage pipeline The company has advancing candidates CB307 and CB693 in clinically relevant programs targeting tumor-specific T cells, with CB307 in PSMA-positive solid tumours. This presents opportunities for BD outreach to oncology-focused CROs, trial sites, and payer discussions around companion diagnostics and targeted immuno-oncology strategies.

Expansion potential Recent announcements include the launch of CB699 and preclinical data on lead candidates, signaling ongoing product diversification. This broadens the addressable market for collaboration in multi-functional Humabody platforms across oncology and potentially other indications.

Investor-backed validation Backed by blue-chip investors such as Sofinnova Partners, BioNTech, Takeda, and Quan Capital, Crescendo shows credible funding and momentum for advancing partnerships, licensing negotiations, and joint development opportunities with large biopharma and biotech players.

Global market reach With a Cambridge, UK base and international collaborations, Crescendo is positioned for global expansion through co-development, regional licensing, or joint ventures, offering sales avenues in Europe, North America, and Asia-Pacific through established partners.